InvestorsHub Logo
Followers 129
Posts 3809
Boards Moderated 0
Alias Born 07/12/2003

Re: None

Monday, 10/11/2021 11:26:02 AM

Monday, October 11, 2021 11:26:02 AM

Post# of 118383
RGBP plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). RGBP owns a valuable patent porfolio.

Key Word: small molecule

Why Small Molecules Are Still a Big Deal

Small molecules continue to play a role in innovative treatments for the four major indications that account for more than half of global pharma growth: oncology, diabetes, autoimmune, and respiratory diseases. For example, small molecule protein kinase inhibitors, of which the FDA has approved 48, are becoming more important in cancer therapy. Another area of growth entails the use of small and large molecules in combination; antibody drug conjugates (ADC), which couple potent small molecule payloads with the targeting capabilities of monoclonal antibodies, allowing for more precise treatment of cancer (and fewer side effects than standard chemotherapy).

Small companies are driving innovation. The vast majority of small molecule drugs in development are held by small or “emerging” companies with fewer than 100 employees. Our analysis suggests that these companies account for approximately 4,400 candidate compounds – or 70 percent of the small-molecule pipeline. These companies are increasingly bringing successful compounds to commercial production, and typically require access to enabling technologies, development, and manufacturing partners to do so.

In short, small molecules are still a big deal – and will be for the foreseeable future. CDMOs with specialized technologies and expertise will continue to help pharma companies advance their compounds. The ability to tailor services to specific customers and drug programs will play an increasingly important role in accelerating patient access to innovative drugs.

See the below link for entire article:

https://themedicinemaker.com/manufacture/why-small-molecules-are-still-a-big-deal